Supriya Lifescience Ltd. announced the outcomes of its Board Meeting held on February 09, 2026. The board approved the Unaudited Financial Results for the Quarter and nine months ended December 31, 2025. Additionally, the board approved the re-appointment of Dr. Neelam Yashpal Arora and the appointment of two new Additional Independent Directors: Mr. Manish Panchal and Mr. Kothandaraman Hari. The board also reconstituted key committees.
Board Meeting Outcomes Announced
The Board of Directors of Supriya Lifescience Ltd. convened on Monday, February 09, 2026, and approved several key items, including the financial results and significant changes to the directorate. The meeting commenced at 03:00 p.m. and concluded at 05:00 p.m.
Unaudited Financial Performance Highlights (Q3 FY2026)
The board approved the Unaudited Financial Results for the quarter and nine months ending December 31, 2025. Key comparative figures from the standalone results show the following (all figures in ₹ million):
- Total Income (Nine Months Ended 31-12-2025): 5,593.57 million, compared to 5,192.16 million in the previous nine-month period.
- Profit/(Loss) for the period from Continuing Operations (Q3 Ended 31-12-2025): 496.75 million.
- Earnings Per Share Basic (Nine Months Ended 31-12-2025): 16.76 per share.
Note: The results also reflect an Exceptional Item of (4.58) million for the nine-month period, related to the adoption of new Labour Codes.
Changes in Directorate Approved
The Board approved key changes to its Independent Director composition, subject to shareholder approval:
- Re-appointment of Dr. Neelam Yashpal Arora (DIN: 01603068): Re-appointed as a Non-Executive Independent Woman Director for a second term of 5 consecutive years, effective from March 25, 2026, to March 24, 2031. Dr. Arora holds extensive experience in commerce, law, and education (over 31 years of teaching).
- Appointment of Mr. Manish Panchal (DIN: 08431492): Appointed as an Additional Independent Director, effective from February 09, 2026, to February 08, 2031. Mr. Panchal is a Business Leader with over 32 years of experience across sectors including Chemicals, Pharmaceuticals, and Logistics, with expertise in Strategy and Investment Banking.
- Appointment of Mr. Kothandaraman Hari (DIN: 08901674): Appointed as an Additional Independent Director, effective from February 09, 2026, to February 08, 2031. Mr. Hari is a capital markets professional with over 28 years of experience, notably contributing to the growth of the National Stock Exchange (NSE).
Reconstitution of Board Committees
Following the directorate changes, the Board also finalized the reconstitution of its standing committees:
Audit Committee
- Chairman: Mr. Hari K.
- Members: Dr. Ganapati Dadasaheb Yadav, Dr. Satish Waman Wagh, and Mr. Manish Panchal.
Nomination and Remuneration Committee
- Chairman: Mr. Hari K.
- Members: Dr. Sunil Subhash Bhagwat and Mr. Manish Panchal.
Stakeholders’ Relationship Committee
- Chairman: Mr. Manish Panchal.
- Members: Dr. Saloni Satish Wagh and Dr. Satish Waman Wagh.
The company confirmed that all appointed directors have provided necessary declarations confirming they are not debarred from holding directorial office.
Source: BSE
